Table 4

Demographic and clinical details of control patients

PatientAgeSexEpilepsy duration (y)Seizure typesSyndromeCurrent drugsFields
129F 14Idiopathic generalisedVPANormal
217F104,5Childhood absenceVPA, TOPNormal
322F 61,3Cryptogenic temporalLTGNormal
427F251,3Symptomatic temporalCBZ, BZD, TOPNormal
556F 21Symptomatic temporalVPANormal
624M 61Cryptogenic temporalVPA, TOPNormal
719F 74,5Idiopathic generalisedLTG, ESMNormal
858F 22,3Symptomatic parietalCBZ, PHTNormal
940F384Idiopathic generalisedPHT, PRMNormal
1035M 23Symptomatic temporalCBZNormal
1147M422,3Cryptogenic temporalCBZNormal
1258F151,3Symptomatic temporalPHT, GBPNormal
1358M561,3Cryptogenic temporalVPA, BZDInconclusive
1453M121,2,3Symptomatic temporalVPA, TOPInconclusive
1519F 21,3Symptomatic temporalCBZ, LTGInconclusive
1634M 34Idiopathic generalisedVPA, LTGInconclusive
  • For drug abbreviations,see table 2.